Glaucoma

Molecular therapy for Glaucoma: Netoglitazone, a blood glucose-lowering drug, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 30/October/2017, 9.29 am
Molecular therapy for Glaucoma: Netoglitazone, a blood glucose-lowering drug, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 30/October/2017, 9.29 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Molecular therapy for Glaucoma: Rivoglitazone, an antihyperglycemic drug, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 29/October/2017, 8.01 am
Molecular therapy for Glaucoma: Rivoglitazone, an antihyperglycemic drug, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 29/October/2017, 8.01 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more
Start Typing